Advertisement

Topics

Companies Related to "Global Development secures future drug candidate development CollegeHill" [Most Relevant Company Matches] - Page: 20 RSS

06:49 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Global Development secures future drug candidate development CollegeHill" found in our extensive corporate database of over 50,000 company records.

Showing "Global Development secures future drug candidate development CollegeHill" Companies 476–500 of 13,000+

Relevant

BiPar Sciences, Inc.

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as mo...


Infinity Pharmaceuticals

The mission of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. We have built a pipeline of innovative product candidates for multiple cancer indications, all of which represent proprietary applications of our expertise in small molecule drug technologies. We believe that our s...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...


TP Therapeutics, Inc.

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drug crizotinib. TP Team is focusing on the design and development of novel chemical identities for established oncogene drivers with high incidence of secondary resistant mutations, ...

Ionix Pharmaceuticals

Ionix Pharmaceuticals is Europe’s first biotechnology company dedicated to the discovery of novel analgesic drugs. Ionix focuses on pain associated with chronic debilitating diseases such as osteoarthritis, rheumatoid arthritis, multiple sclerosis and diabetic neuropathy. Develop a world-class IP portfolio in novel drug targets and lead series for analgesic medicines with targeted mode of action...

AVI BioPharma

AVI BioPharma is an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon three platform technologies: - therapeutic cancer vaccines, - gene-targeted drugs (antisense), and, - drug delivery technologies.The Company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. The Company ...

ChemDiv, Inc.

ChemDiv, Inc. (ChemDiv) is a global chemistry-driven contract research organization focused on the delivery of new scientific innovation and a range of products and services that meet the drug discovery needs of its partners. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class human and ...

TransPharma Medical Ltd.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing its proprietary active transdermal drug delivery technology. The company aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through indep...

Protiveris Inc.

Protiveris Inc. is the world's leading technology company dedicated to the commercialization of micro- and nanocantilever systems for academic research, drug discovery and development, bio-defense and diagnostic applications.With corporate headquarters in Rockville, Maryland, Protiveris aims to become the pre-eminent global supplier of label-free technology. Its proprietary cantilever technology h...

Karo Bio AB

Karo Bio is an innovative drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals. The company has a strong project portfolio primarily targeting metabolic diseases such as diabetes, obesity, atherosclerosis and dyslipidemia. Karo Bio has expanded from being a drug discovery company by adding in-house preclinical development resources a...

Incyte

Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build signifi...

Lipocine, Inc.

Lipocine Inc. is a specialty pharmaceutical company developing innovative products for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine’s lead product candidate, LPCN 1021, is Phase III ready and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Th...

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics, Inc. is a development stage pharmaceutical company focused on treating a broad range of addictions and obesity where the major clinical challenge is a limited range of effective drug therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions that drive craving and relapse associated with ...

MdBio, Inc.

MdBio, a division of the Tech council of Maryland, is a private non-profit corporation that seeks to unify, empower and advance Maryland’s bioscience industry, providing comprehensive support services to its members and the broader community. Areas of emphasis include corporate and business development, networking and community building, education and workforce development, and communicati...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

NeoImmuneTech

NeoImmuneTech, a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, HyLeukin-7, in the US and EU. Based in Rockville, Maryland, NeoImmuneTech has the core competency of global clinical and business development with a strong scientific focus and a broad network of global leading R&...

ConSynance Therapeutics, Inc.

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. The company’s pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. ConSynance are collaborating with Chengdu SciMount Pharmatech Co., Ltd., a drug discov...

Lionbridge Technologies, Inc.

Lionbridge Technologies, Inc. (Nasdaq: LIOX) is a provider of translation, development and testing solutions. Lionbridge combines global resources with proven program management methodologies to serve as an outsource partner throughout a client's product and content lifecycle - from development to translation, testing and maintenance. Global organizations rely on Lionbridge services to increase in...

Acceleration Laboratory Services Inc.

Acceleration Laboratory Services Inc. is a subsidiary of Acceleration Scientific LLC, a leader in drug development and contract research (CRO). Since 2003, Acceleration has been the foremost Contract Solutions Provider for the pharmaceutical research, animal health, and nutraceuticals industry. Based in Kansas City, MO., it is ideally located for rapid res...

Genstruct Inc.

Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. By developing Causal Network(TM) models for complex biological systems, Genstruct develops a deep molecular understanding of diseases and drug action, and designs mechanistic biomarkers and molecular diagnostics ...

Pharmaron Holdings Limited

Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission....

Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases. The Company's lead product candidate, NT-501, is currently in late-stage clinical development for advanced dry age-related macular degeneration (dry AMD) and retinitis pigmentosa (RP). The Company's portfolio of product candidates also includes treatments for wet AMD. All of Neurotech's development pro...

Ironwood Pharmaceuticals, Inc. and Bionomics Limited

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The efficacy portion of linaclotide’s dev...

AngioDesign, Inc

AngioDesign, Inc. is a new biotech start-up company focussed on the design of improved, next-generation drugs for proven disease targets. True validation of therapeutic targets in the clinic is by far the most costly part of the drug discovery and development process. AngioDesign will short-circuit the process by applying structure-guided drug design to proven disease targets and developing 2nd-ge...

MDS Inc.

MDS has more than 8,800 highly skilled people in 28 countries. We provide a diverse range of superior products and services to increase our customers’ speed, precision and productivity in the drug development and disease diagnosis processes. We are a global, values-driven health and life sciences company, recognized for our reliability and collaborative relationships as we help create bette...


More From BioPortfolio on "Global Development secures future drug candidate development CollegeHill"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks